Retinal vein occlusion: everything you need to know

Written by: Dr Gabriella De Salvo
Published: | Updated: 23/04/2023
Edited by: Robert Smith

Retinal vein occlusion is a condition that isn’t uncommon in people under the age of 60, though it’s more prevalent in older people.
 

retinal veil occlusion

 

We recently spoke with Dr Gabriella De Salvo, internationally-recognised consultant ophthalmologist, to find out the answers to some of your FAQs regarding this condition. Read on to find out exactly what retinal vein occlusion is, how dangerous it is, what the symptoms are, how it’s diagnosed and treated.
 

What is retinal vein occlusion?

 

Retinal vein occlusion (RVO) is a temporary obstruction of one of the retinal veins, resulting in engorgement and dilation of the blood vessels involved. RVO causes spread of retinal haemorrhages, possible retinal damage (ischaemia) and macular oedema (fluid accumulation), affecting the vision.

 

RVO can affect the main retinal vein. In this case, it is called central retinal vein occlusion (CRVO) or, more frequently, one of its branches, therefore called branch retinal vein occlusion (BRVO). RVOs represent the second most common vascular cause in the world, causing decreased vision. The risk for the other eye to be affected ranges between 5 - 10%.
 

What are the early and late-stage symptoms of retinal occlusion?

 

Patients affected by RVO may experience abrupt, painless loss of vision, sometimes preceded by temporary loss of vision of short duration called amaurosis fugax. Accumulation of fluid at the centre of the retina is called macular oedema and is responsible for the decrease in vision. Macular oedema can be associated with both CRVO and BRVO. In the case of ischaemic CRVO also the peripheral vision will be affected, while in BRVO, usually only one quadrant of the visual field will be affected, causing blurred vision in that particular field of vision.
 

What are the risk factors for retinal vein occlusion?

 

Risk factors for RVO can be local or systemic. Among the first ones, open-angle glaucoma is the most common. Common systemic risk factors include arterial hypertension, dyslipidaemia, diabetes mellitus, thrombophilia. RVO can be caused by other systemic inflammatory diseases, such as lupus erythematosus, Behçet's disease and sarcoidosis, and can be associated with various haematologic conditions such as leukaemia and lymphoma. Smoking and obesity are also risk factors.
 

Is retinal vein occlusion an emergency?

 

Patients with RVO need to seek medical advice as soon as possible to rule out any possible underlying disease causing the RVO. They also need to be seen within a few weeks by an ophthalmologist in order to get the diagnosis, being treated if necessary and avoid possible complications, such as neovascular glaucoma (new blood vessels associated with increased intraocular pressure) or bleeding inside the eye (vitreous haemorrhage).
 

How is retinal vein occlusion diagnosed?

 

RVO is diagnosed at slit lamp examination by an ophthalmologist, visual acuity is measured, dilating drops then will help the doctor to examine the retina. A retina scan called optical coherence tomography (OCT) is done to evaluate the presence of fluid. In the case of ischaemia or possible complications, such as the formation of new blood vessels, a dye test called fluorescein angiography may be needed to study the retinal circulation and plan possible future interventions, such as injections inside the eye (intravitreal injections of anti-VEGF or steroid implant) and/or retinal laser.
 

What is the outlook for retinal vein occlusion patients?

 

Treatment with anti-VEGF and/or steroid eye implants has significantly improved the long-term prognosis of RVOs. Treatment improves both the vision and the macular oedema, except in those cases with ischaemic maculopathy. About 1/3 of CRVO cases develop retinal ischaemia. Therefore, it is fundamental to continue monitoring the retina and treat possible complications such as neovascular glaucoma.
 

 

If you believe you may have retinal vein occlusion, get in contact with a leading ophthalmologist such as Dr Gabriella De Salvo. Click here to visit her Top Doctors profile today.

By Dr Gabriella De Salvo
Ophthalmology

Dr Gabriella De Salvo is an internationally recognised consultant ophthalmologist who is based in Southampton and has over 20 years of experience. She provides highly professional and personalised care to adults and paediatric patients aged 3 and older.

Her areas of expertise include the diagnosis and treatment of medical retina conditions such as age-related macular degeneration (AMD)retinal vein occlusion, diabetic retinopathy and central serous chorioretinopathy. Furthermore, she regularly performs procedures such as intravitreal injections of anti-VEGF and intravitreal steroid implants. In fact, she has performed over 10,000 intravitreal injections of VEGF and steroid implants for retinal conditions. As an expert in diagnosing and treating challenging cases, she is available to provide a second opinion for rare and complex retinal disorders as well as for other conditions. 

Based on the work she has published, she ranks in the top 2% of medical retinal specialists in the world.

Dr De Salvo graduated as Medical Doctor at the University of Messina in Italy and completed her specialist training in Ophthalmology at the University of Palermo, Italy. During her training she won various scholarships and was able to deepen her studies at the Wills Eye Hospital in Philadelphia in the USA and at the University hospital in Vienna, Austria. She completed over a year of advanced training in Medical Retina at Moorfields Eye Hospital, London. She is a keen researcher and lecturer and regularly publishes her work in international peer-reviewed journals and is the principal investigator in various clinical trials. She is actively involved in the teaching of ophthalmologists, allied health professionals and medical students.

Dr De Salvo also works in collaboration with prestigious pharmaceutical companies in the development and research of new medicaments. Specifically she works with Novartis, Bayer, Roche, AbbVie, Boehringer Ingelheim, Teva, Heidelberg Engineering. She sits on national and international advisory boards for the development of innovative molecules to treat eye diseases. She is also Clinical Outcome Lead for Ophthalmology at University Hospital Southampton. She is a fellow of the Royal College of Ophthalmologist and is also a certified trainer and appraiser for the Royal College of Ophthalmologists. She has won various prizes during her career and a few clinical excellence awards.

In addition to ophthalmology, she has a special interest in facial and anti-wrinkle assessment.

View Profile

Overall assessment of their patients


  • Related procedures
  • Microdermoabrasion
    Microneedling
    Dark circles
    Mesotherapy
    Facelift
    Neck lift
    Botulinum toxin (Botox™)
    Dermal fillers
    Peeling
    Facial paralysis
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.